RT Journal Article
T1 Levofloxacin vs. Azithromycin Pharmacodynamic Activity Against S. pneumoniae and H. influenzae with Decreased Susceptibility to Amoxicillin/Clavulanic Acid
A1 Alou Cervera, Luis
A1 Aguilar, Lorenzo
A1 Sevillano Fernández, David
A1 Giménez, María José
A1 González Hidalgo, Natalia
A1 Echeverría, Olatz
A1 Torrico, Martha
A1 Martín, Jose Emilio
A1 Valdés, Laura
A1 Prieto Prieto, José
AB Resistant clones/phenotypes are putting into question the activity of commonly used beta-lactams, thus prompting the need for alternative options. A 500 mg levofloxacin vs. azithromycin once daily pharmacodynamic simulation was performed against 10(8) cfu/ml of four Streptococcus pneumoniae strains (exhibiting higher amoxicillin than penicillin MIC) and four Haemophilus influenzae strains: beta-lactamase producing, BLNAR (beta-lactamase-negative ampicillin-resistant) and BLPACR (beta-lactamase-positive amoxicillin/clavulanate-resistant). High levofloxacin AUC/MIC values for H. influenzae, and values of 50-100 for S. pneumoniae produced a >5 log(10) reduction at 24h for all strains. Azithromycin AUC/MIC values of approximately 10 were needed to obtain a 2-3 log(10) reduction of S. pneumoniae initial inocula, but lower AUC/MIC values (of approximately 6) obtained > or =3 log(10) reduction against all strains of H. influenzae. While in vitro simulated serum concentrations of levofloxacin were bactericidal at the end of the dosing interval against all S. pneumoniae strains and azithromycin against the susceptible ones, both antimicrobials achieved this endpoint against the BLNAR and BLPACR strains.
PB Taylor & Francis
SN 1120-009X
YR 2007
FD 2007-12
LK https://hdl.handle.net/20.500.14352/107166
UL https://hdl.handle.net/20.500.14352/107166
LA eng
NO Alou L, Aguilar L, Sevillano D, Giménez MJ, González N, Echeverría O, Torrico M, Martín JE, Valdés L, Prieto J. Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid. J Chemother. 2007 Dec;19(6):670-2.
NO GlaxoSmithKline S.A.
DS Docta Complutense
RD 17 abr 2025